IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v41y2018i11d10.1007_s40264-018-0681-z.html
   My bibliography  Save this article

What Future Healthcare Professionals Need to Know About Pharmacovigilance: Introduction of the WHO PV Core Curriculum for University Teaching with Focus on Clinical Aspects

Author

Listed:
  • Rike van Eekeren

    (Netherlands Pharmacovigilance Centre Lareb, WHO Collaborating Centre For Pharmacovigilance in Education and Patient Reporting
    University of Groningen, Groningen Research Institute of Pharmacy, PharmacoTherapy, -Epidemiology and -Economics)

  • Leàn Rolfes

    (Netherlands Pharmacovigilance Centre Lareb, WHO Collaborating Centre For Pharmacovigilance in Education and Patient Reporting
    University of Groningen, Groningen Research Institute of Pharmacy, PharmacoTherapy, -Epidemiology and -Economics)

  • Andries S. Koster

    (University of Utrecht)

  • Lara Magro

    (University of Verona)

  • Gurumurthy Parthasarathi

    (JSS University)

  • Hussain Al Ramimmy

    (Ministry of Health)

  • Tim Schutte

    (VU University Medical Center
    RECIPE (Research and Expertise Center in Pharmacotherapy Education))

  • Daisuke Tanaka

    (WHO)

  • Eugène van Puijenbroek

    (Netherlands Pharmacovigilance Centre Lareb, WHO Collaborating Centre For Pharmacovigilance in Education and Patient Reporting
    University of Groningen, Groningen Research Institute of Pharmacy, PharmacoTherapy, -Epidemiology and -Economics)

  • Linda Härmark

    (Netherlands Pharmacovigilance Centre Lareb, WHO Collaborating Centre For Pharmacovigilance in Education and Patient Reporting)

Abstract

Adverse drug reactions (ADRs) can cause serious health problems, as shown in studies about drug-related hospitalizations. To build knowledge of and raise awareness about ADRs among healthcare professionals, more education in the field of ADRs and pharmacovigilance (PV) is needed. No standard exists for teaching PV at universities for medical, pharmacy, dentistry and nursing students, so a core curriculum needs to be developed to teach important aspects of PV to students. In September 2016, a stakeholders’ meeting was initiated on behalf of the World Health Organization (WHO) and organized by the Netherlands Pharmacovigilance Centre Lareb. This meeting addressed and agreed on the PV competencies students need to develop and what key aspects of the subject should be taught. Five key aspects were identified: understanding the importance of PV in the context of pharmacotherapy, and preventing, recognizing, managing and reporting ADRs. Since time and resources for PV education are limited, elements of the WHO PV core curriculum for university teaching were designed to be integrated into existing courses but can be used as a stand-alone programme. The basis of and outline for the WHO PV core curriculum for university teaching are addressed in this paper. It is expected that PV competencies for students are vital for their contribution to safe use of medicines in the future. In addition, this article aims to stimulate discussion on this subject and promote collaboration between universities, national PV centres and other stakeholders to integrate key aspects of PV in their educational programmes.

Suggested Citation

  • Rike van Eekeren & Leàn Rolfes & Andries S. Koster & Lara Magro & Gurumurthy Parthasarathi & Hussain Al Ramimmy & Tim Schutte & Daisuke Tanaka & Eugène van Puijenbroek & Linda Härmark, 2018. "What Future Healthcare Professionals Need to Know About Pharmacovigilance: Introduction of the WHO PV Core Curriculum for University Teaching with Focus on Clinical Aspects," Drug Safety, Springer, vol. 41(11), pages 1003-1011, November.
    • Handle: RePEc:spr:drugsa:v:41:y:2018:i:11:d:10.1007_s40264-018-0681-z
    DOI: 10.1007/s40264-018-0681-z
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-018-0681-z
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40264-018-0681-z?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Mulugeta Tarekegn Angamo & Leanne Chalmers & Colin M. Curtain & Luke R. E. Bereznicki, 2016. "Adverse-Drug-Reaction-Related Hospitalisations in Developed and Developing Countries: A Review of Prevalence and Contributing Factors," Drug Safety, Springer, vol. 39(9), pages 847-857, September.
    2. Leàn Rolfes & Florence Hunsel & Katja Taxis & Eugène Puijenbroek, 2016. "The Impact of Experiencing Adverse Drug Reactions on the Patient’s Quality of Life: A Retrospective Cross-Sectional Study in the Netherlands," Drug Safety, Springer, vol. 39(8), pages 769-776, August.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Janet Sultana & Ugo Moretti & Antonio Addis & Pia Caduff & Annalisa Capuano & Agnes Kant & Joan-Ramon Laporte & Marie Lindquist & June Raine & Daniele Sartori & Gianluca Trifirò & Marco Tuccori & Maur, 2019. "Workshop on the Italian Pharmacovigilance System in the International Context: Critical Issues and Perspectives," Drug Safety, Springer, vol. 42(5), pages 683-687, May.
    2. Monira Alwhaibi & Noha A Al Aloola, 2020. "Healthcare students' knowledge, attitude and perception of pharmacovigilance: A systematic review," PLOS ONE, Public Library of Science, vol. 15(5), pages 1-12, May.
    3. Joanne Barnes & Rachael Butler, 2020. "Community Pharmacists’ Views and Experiences with ADR Reporting for Complementary Medicines: A Qualitative Study in New Zealand," Drug Safety, Springer, vol. 43(11), pages 1157-1170, November.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Solomon Shiferaw Nadew & Kidanemariam G/Michael Beyene & Solomon Worku Beza, 2020. "Adverse drug reaction reporting practice and associated factors among medical doctors in government hospitals in Addis Ababa, Ethiopia," PLOS ONE, Public Library of Science, vol. 15(1), pages 1-19, January.
    2. Cristiano Matos & Gerda Weits & Florence Hunsel, 2019. "The Role of European Patient Organizations in Pharmacovigilance," Drug Safety, Springer, vol. 42(4), pages 547-557, April.
    3. Sarah Watson & Rebecca E. Chandler & Henric Taavola & Linda Härmark & Birgitta Grundmark & Alem Zekarias & Kristina Star & Florence Hunsel, 2018. "Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre," Drug Safety, Springer, vol. 41(2), pages 203-212, February.
    4. Leàn Rolfes & Florence Hunsel & Laura Linden & Katja Taxis & Eugène Puijenbroek, 2017. "The Quality of Clinical Information in Adverse Drug Reaction Reports by Patients and Healthcare Professionals: A Retrospective Comparative Analysis," Drug Safety, Springer, vol. 40(7), pages 607-614, July.
    5. Mulugeta Tarekegn Angamo & Colin Michael Curtain & Leanne Chalmers & Daniel Yilma & Luke Bereznicki, 2017. "Predictors of adverse drug reaction-related hospitalisation in Southwest Ethiopia: A prospective cross-sectional study," PLOS ONE, Public Library of Science, vol. 12(10), pages 1-17, October.
    6. Cristina Monteiro & Beatriz Dias & Maria Vaz-Patto, 2021. "Headache as an Adverse Reaction to the Use of Medication in the Elderly: A Pharmacovigilance Study," IJERPH, MDPI, vol. 18(5), pages 1-11, March.
    7. Leàn Rolfes & Michelle Haaksman & Florence van Hunsel & Eugène van Puijenbroek, 2020. "Insight into the Severity of Adverse Drug Reactions as Experienced by Patients," Drug Safety, Springer, vol. 43(3), pages 291-293, March.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:41:y:2018:i:11:d:10.1007_s40264-018-0681-z. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.